Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

"Zentalis reported significant progress in the development of azenosertib in 2024 and made important advancements this year. We plan to maintain strong execution on the late-stage development of ...

Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, ...

In downstream processing of biopharmaceutical products, protein aggregation presents one of the main risks in terms of ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

Abbott will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 ...

The Arkansas Integrative Metabolic Research Center has received a $263,813 Women's Health Supplement award from the National Institutes of Health to explore how obesity-induced changes in tissue ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

Among the many marvels of life is the cell’s ability to divide and thus enable organisms to grow and renew themselves.

Among the many marvels of life is the cell's ability to divide and thus enable organisms to grow and renew themselves.